B+
Bull case
25%
Probability
Target price
$380.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
NTRA
NateraDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Q2 results show sustained commercial acceleration, especially in oncology, alongside improving gross margin and a substantial guidance increase. Regulatory approvals, expanded Medicare coverage, and product enhancement support continued adoption [#SEC-8K-2026-08-06].
Posture
Defensive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-10-26.
What can break
Gross margin remains sensitive to revenue-accrual estimates and cost-of-revenue execution.
Momentum
98
Value
48
Sentiment
35
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $335.00 · Bull $380.00 · Bear $270.00Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $411.39
Why
Momentum98 · Δ7d -0.1
Value48 · Δ7d -0.0
Sentiment35 · Δ7d -3.3
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 3 setup hits (3d) with net bullish as of 2026-10-26.
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Gross margin remains sensitive to revenue-accrual estimates and cost-of-revenue execution.
- • Post-earnings momentum may reverse if future volume or oncology growth fails to sustain the current pace.
- • The post-print rally may have discounted much of the guidance increase.
Catalyst clock
2026-08-06
Q2 2026 results and raised revenue outlook
Lead driver: Value · See fundamentals
Momentum
98
8% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.3
Value
48
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
35
45% active weight
Current posture
7d trendSoftening
Δ7d
-3.3
Δ21d
-4.5
Why this grade
Composite grade D. Momentum 97.8 / Value 47.8 / Sentiment 35.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$335.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$270.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$58.36B
Beta
1.63
Shares Out
144.14M
P/E (TTM) · Derived
-265.9
P/S (TTM)
15.61
P/FCF (TTM)
353.07
Rev YoY
+37.7%
EPS YoY
-36.8%
Gross Margin
+64.7%
Op Margin
-10.6%
Net Debt
-$861.76M
Current Ratio
3.00
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data